What This Page Covers
HBOT reduced fibromyalgia pain scores significantly across 9 studies involving 288 patients (BMJ Open, 2023). Clinical response rates for inflammatory bowel disease reached 86% for both ulcerative colitis and Crohn’s. For Lyme disease and chronic fatigue, the data is thinner but emerging. Chronic conditions represent the most complex territory in HBOT research because they involve systemic pathology across multiple organ systems. Here is what the evidence actually supports, condition by condition.
This page covers metabolic disease, autoimmune conditions, pulmonary disease, chronic infections, and post-infectious syndromes. We are transparent throughout about where evidence is strong, where it is preliminary, and where HBOT remains speculative.
What Does the Research Say?
| Condition | Evidence Level | Strength | FDA Status |
|---|---|---|---|
| Diabetic foot ulcers | High (multiple SRs, RCTs) | Strong | FDA-cleared |
| Fibromyalgia | Moderate (RCTs, meta-analyses) | Moderate | Off-label |
| IBD (Crohn’s, UC) | Low-Moderate (mostly case series) | Emerging | Off-label |
| Long COVID | Low-Moderate (1 RCT, registry) | Emerging | Off-label |
| Chronic wound healing | Moderate-High | Moderate-Strong | FDA-cleared |
| CRPS | Very low | Insufficient | Off-label |
| CIRS | Very low (case report) | Insufficient | Off-label |
The Case for HBOT in Chronic Disease
Many chronic diseases share a common pathological feature: tissue-level hypoxia. Whether from impaired microvascular circulation in diabetes, autoimmune-driven vascular inflammation in lupus or MS, or post-infectious autonomic dysregulation in long COVID, chronically sick tissue tends to be oxygen-deprived tissue. HBOT directly addresses this by saturating plasma with dissolved oxygen, reaching areas of compromised perfusion that normal circulation cannot adequately supply.
Beyond oxygen delivery, HBOT triggers suppression of pro-inflammatory cytokines, upregulation of antioxidant gene expression via Nrf2 pathways, stem cell mobilization from bone marrow, and stimulation of mitochondrial biogenesis. A 2026 systematic review of 11 RCTs involving 480 chronic pain patients found consistent within-group improvements in pain, functioning, and quality of life8.
For the evidence behind these mechanisms, visit our HBOT research hub. For side effects and risks, see our guide to hyperbaric chamber side effects.
Conditions Covered
Fibromyalgia
Fibromyalgia has the most developed HBOT evidence base among chronic pain conditions. A landmark 2015 crossover RCT of 60 female patients found that 40 HBOT sessions led to significant improvement in all fibromyalgia symptoms and quality of life. SPECT brain imaging showed correction of abnormal activity patterns associated with central sensitization1.
“A 2023 systematic review in BMJ Open analyzed 9 studies of 288 fibromyalgia patients and found HBOT significantly reduced pain (p<0.001) and improved fatigue, function, and sleep, though 23.8% experienced mild adverse events."
Chen et al., 2023, BMJ Open
Three meta-analyses have since been published. Chen et al. (2023) analyzed 9 studies of 288 patients and found significant pain reduction (SMD=-1.56, p<0.001) with improvements in tender points, fatigue, function, and sleep2. Kulshreshtha et al. (2024) analyzed 5 RCTs of 180 patients and found decreased tender points, increased pain threshold, and improved quality of life4.
fibromyalgia patients across 9 studies showed significant pain reduction with HBOT
Chen et al., 2023, BMJ Open
There is an important caveat. The only truly double-blinded FM study (Raffeiner et al., 2020, n=12) found no significant difference between HBOT and placebo (hyperbaric air). Both groups improved, suggesting a possible placebo or pressure effect5. All positive fibromyalgia studies either lacked blinding or used a waiting-list control. The hyperbaric chamber experience itself may contribute to outcomes independent of oxygen.
Our full article on HBOT for fibromyalgia covers the complete evidence landscape.
Diabetes
Diabetic foot ulcers that are failing to heal and threatening limb amputation are one of the 14 FDA-cleared indications for HBOT. Multiple systematic reviews support HBOT as adjunctive treatment, with demonstrated reductions in amputation rates9. Medicare covers HBOT for this indication when properly documented. Beyond wound healing, HBOT has been studied for diabetic neuropathy and retinopathy with supportive but not definitive evidence. Our article on HBOT for diabetes covers both established and emerging applications. The diabetic foot ulcer data page has the clinical numbers.
Autoimmune Conditions
HBOT’s immunomodulatory effects make it conceptually attractive for autoimmune disease. By modulating cytokine profiles and reducing oxidative stress, HBOT may help regulate the dysregulated immune response underlying conditions like lupus, rheumatoid arthritis, and Sjogren’s syndrome. Clinical research is sparse and largely confined to case reports and small series. Our article on HBOT for autoimmune conditions presents the limited evidence honestly.
Inflammatory Bowel Disease
A 2021 systematic review of 19 studies (3 RCTs, 16 case series) found clinical response rates of 86% for luminal ulcerative colitis, 86% for luminal Crohn’s disease, and 80% for perianal Crohn’s. Minor adverse events occurred in 10.5% of patients7.
“A meta-analysis of IBD studies found clinical response rates of 86% for both ulcerative colitis and Crohn’s disease, though the evidence came predominantly from uncontrolled case series.”
Siw et al., 2021, Journal of the Canadian Association of Gastroenterology
Critical context: these are mostly uncontrolled case series. True efficacy is unknown.
Long COVID
Long COVID has become one of the most actively investigated areas in HBOT research. A randomized controlled trial by Zilberman-Itskovich et al. (2022) found that 40 HBOT sessions significantly improved cognitive function, quality of life, fatigue, and psychiatric symptoms compared to sham treatment. Brain SPECT imaging showed measurable improvement in cerebral perfusion. A 2024 follow-up by Catalogna et al. confirmed the durability of these improvements. Our articles on HBOT for long COVID symptoms and long COVID clinical data cover the full evidence.
COPD
COPD presents particular complexity: patients have already compromised lungs, and their hypoxic drive to breathe can be affected by high-dose oxygen. HBOT is contraindicated in some COPD patients. Read our article on HBOT for COPD for the clinical considerations.
Lyme Disease
Chronic Lyme and post-treatment Lyme disease syndrome (PTLDS) are areas of significant medical controversy. Some practitioners use HBOT as part of comprehensive protocols. The published evidence is mostly case reports and small series. We do not endorse HBOT as a proven Lyme treatment but review the available evidence fairly in our article on HBOT for Lyme disease.
Multiple Sclerosis
HBOT has been studied in MS since the 1980s. A Cochrane systematic review concluded that evidence is insufficient to recommend HBOT as standard MS treatment, though some patients report symptomatic improvements, particularly in fatigue and bladder function. Our article on HBOT for multiple sclerosis covers the full research history.
Managing Expectations for Chronic Conditions
HBOT may address some of the mechanisms driving your condition without resolving others. If you’ve exhausted conventional options, the most important things are to work with a physician who understands both your condition and HBOT, to define what you are measuring, and to give the therapy an adequate trial (typically 20 to 40 sessions) before drawing conclusions.
What to Discuss With Your Doctor
Ask whether your primary management plan is optimized before adding HBOT. If your diabetes is not well-controlled, your autoimmune disease is untreated, or your COPD medications are not optimized, HBOT is unlikely to compensate for those gaps.
Understand the financial reality. Most chronic condition applications are off-label, meaning out-of-pocket costs apply. Our cost guide provides a realistic framework. And before starting, read our overview of side effects, particularly if you have pulmonary or cardiovascular comorbidities.
Related HBOT Guides
Chronic conditions frequently involve neurological components. Research on HBOT for brain and neurological conditions covers conditions like MS, Parkinson’s, and cognitive decline that often intersect with systemic chronic disease. For a full explanation of how hyperbaric oxygen therapy works and what pressures are used clinically, see the complete hyperbaric chamber guide.
References
- Efrati S, et al. “Hyperbaric oxygen therapy can diminish fibromyalgia syndrome: prospective clinical trial.” PLoS ONE, 2015;10(5):e0127012. DOI: 10.1371/journal.pone.0127012
- Chen X, et al. “Efficacy and safety of HBOT for fibromyalgia: a systematic review and meta-analysis.” BMJ Open, 2023;13(1):e062322. DOI: 10.1136/bmjopen-2022-062322
- Cao CF, et al. “Effectiveness of hyperbaric oxygen for fibromyalgia: a meta-analysis of randomized controlled trials.” Clinics and Practice, 2023;13(3):53. DOI: 10.3390/clinpract13030053
- Kulshreshtha P, et al. “Assessment of efficacy and safety of HBOT on pain in fibromyalgia patients.” Journal of Medical Evidence, 2024. DOI: 10.4103/jme.jme_102_23
- Raffeiner B, et al. “HBOT in fibromyalgia patients: double-blind prospective clinical trial.” Annals of the Rheumatic Diseases, 2020;79(Suppl 1):1947. DOI: 10.1136/annrheumdis-2020-eular.5927
- Dulai PS, et al. “The safety and efficacy of HBOT for inflammatory bowel disease.” Alimentary Pharmacology & Therapeutics, 2014;39(12):1266-1275. DOI: 10.1111/apt.12753
- Siw K, et al. “The effectiveness and safety of HBOT in IBD: a systematic review and meta-analysis.” Journal of the Canadian Association of Gastroenterology, 2021;4(Suppl 1):A158. DOI: 10.1093/JCAG/GWAB002.156
- Leys A, et al. “HBOT in managing chronic pain syndromes: a systematic review.” Journal of Pain Research, 2026. DOI: 10.2147/JPR.S597243
- Li W, et al. “HBOT for chronic diabetic foot ulcers: an overview of systematic reviews.” Diabetes Research and Clinical Practice, 2021;176:108862. DOI: 10.1016/j.diabres.2021.108862
- Ablin J, et al. “HBOT compared to pharmacological intervention in fibromyalgia patients following TBI.” PLoS ONE, 2023;18(3):e0282406. DOI: 10.1371/journal.pone.0282406
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
